COVID-19 in ocrelizumab-treated people with multiple sclerosis.

Abstract:

BACKGROUND:There are limited data on the impact of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on people with multiple sclerosis (MS). OBJECTIVE:To better understand SARS-CoV-2 infection in ocrelizumab-treated people with MS. METHODS:Internal Roche/Genentech data sources: Cases of COVID-19 from ongoing Roche/Genentech clinical trials and from post-marketing use of ocrelizumab until July 31, 2020 were identified and assessed using descriptive statistics. External real-world data (RWD) source: An MS COVID-19 cohort and an ocrelizumab-treated MS COVID-19 cohort were identified and assessed from the OPTUMⓇ de-identified COVID-19 electronic health record (EHR) database. RESULTS:Roche/Genentech clinical trial data: There were 51 (1.3%) suspected or confirmed cases of COVID-19 identified from 4,000 patients ongoing in 10 Roche/Genentech clinical trials. Of these, 26 (51%) were confirmed COVID-19 and 25 (49%) were suspected COVID-19. Sixteen (31.4%) patients were hospitalized. COVID-19 severity was mild to moderate in most patients (35, 68.6%). Ten (19.6%) patients had severe disease and there were three (5.9%) fatal cases. Most patients (43, 84.3%) recovered or were recovering. There was no association apparent between duration of exposure to ocrelizumab and COVID-19. Among COVID-19 patients with previous serum immunoglobulin status (27/51, 52.9%), all (27/27, 100%) had IgG levels within the normal range. Roche/Genentech post-marketing safety database data: There were 307 post-marketing cases of COVID-19 in the Roche/Genentech global safety database. Of these, 263 (85.7%) were confirmed and 44 (14.3%) were suspected COVID-19. 100 (32.6%) patients were hospitalized. COVID-19 was asymptomatic, mild or moderate in 143 (46.6%) patients, severe in 52 (16.9%) patients, and critical in 15 (4.9%) patients. There were 17 (5.5%) fatal cases. Information on severity was not reported in 80 (26.1%) cases. Most patients (211, 68.7%) recovered or were recovering at the time of the report. External RWD data source: As of July 13, 2020, the OPTUMⓇ database included EHRs for almost 1.2 million patients with suspected COVID-19, 130,500 of whom met the criteria for confirmed/clinically diagnosed COVID-19. A total of 357 patients with MS with confirmed COVID-19 were identified. Forty-eight (13.4%) were treated with ocrelizumab, of whom 12 (25.0%) were hospitalized and one died (2.1%). Similar rates of hospitalization, invasive ventilation, and death were observed in the ocrelizumab-treated and non-ocrelizumab-treated MS cohorts. Across the Roche/Genentech and RWD sources assessed, age, male sex, and the presence of comorbidities such as hypertension were associated with a more severe disease course of COVID-19. There was a higher number of comorbidities present in hospitalized versus non-hospitalized patients. CONCLUSIONS:This assessment provides evidence that COVID-19 in ocrelizumab-treated people with MS is predominantly mild to moderate in severity with most patients not requiring hospitalization; in line with data reported from the general population and MS datasets. Risk factors known to be associated with severe COVID-19 outcomes in the general population also appear to influence COVID-19 severity in ocrelizumab-treated people with MS. Case fatality rates for ocrelizumab-treated people with MS were within published ranges for the general population and other MS cohorts.

authors

Hughes R,Whitley L,Fitovski K,Schneble HM,Muros E,Sauter A,Craveiro L,Dillon P,Bonati U,Jessop N,Pedotti R,Koendgen H

doi

10.1016/j.msard.2020.102725

subject

Has Abstract

pub_date

2020-12-30 00:00:00

pages

102725

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(20)30799-9

journal_volume

49

pub_type

杂志文章
  • Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes.

    abstract:BACKGROUND:The appropriate treatment target in multiple sclerosis (MS) is unclear. Lack of magnetic resonance imaging (MRI) lesion activity, a component of the no evidence of disease activity concept, has been proposed as a treatment target in MS. We used our MS database to investigate whether aggressively pursuing MRI...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.07.017

    authors: Conway DS,Thompson NR,Cohen JA

    更新日期:2016-09-01 00:00:00

  • Patient needs and preferences in relapsing-remitting multiple sclerosis: A systematic review.

    abstract:BACKGROUND:Considering the multiple treatments approved for multiple sclerosis (MS) by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), determining a treatment strategy for patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) can be challenging. To date, an overv...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.101929

    authors: Visser LA,Louapre C,Uyl-de Groot CA,Redekop WK

    更新日期:2020-01-02 00:00:00

  • Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study.

    abstract:BACKGROUND:Growing evidence supports the efficacy of restorative cognitive training in people with multiple sclerosis (PwMS), but the effects vary across individuals. Differences in treatment efficacy may be related to baseline individual differences. We investigated clinical characteristics and MRI variables to predic...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.026

    authors: Fuchs TA,Ziccardi S,Dwyer MG,Charvet LE,Bartnik A,Campbell R,Escobar J,Hojnacki D,Kolb C,Oship D,Pol J,Shaw MT,Wojcik C,Yasin F,Weinstock-Guttman B,Zivadinov R,Benedict RHB

    更新日期:2019-09-01 00:00:00

  • A temporal analysis of bilateral gait coordination in people with multiple sclerosis.

    abstract:BACKGROUND:Gait performance often dictates an individual's ability to navigate the dynamic environments of everyday living. With each stride, the lower extremities move through phases of stance, swing, and double support. Coordinating these motions with high accuracy and consistency is imperative to constraining the ce...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102445

    authors: Richmond SB,Swanson CW,Peterson DS,Fling BW

    更新日期:2020-10-01 00:00:00

  • A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.

    abstract::Fingolimod, taken orally once per day, is approved for the treatment of relapsing-remitting multiple sclerosis (MS). It should be stopped at least two months before conception as it is not considered safe during pregnancy or when breast feeding. In vitro and animal studies have found a possibly increased risk of conge...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.02.015

    authors: Navardi S,Sahraian MA

    更新日期:2018-04-01 00:00:00

  • Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

    abstract:BACKGROUND:Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS). OBJECTIVE:to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS. METHOD:CXCL13 was...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102281

    authors: Olesen MN,Nilsson AC,Pihl-Jensen G,Soelberg KK,Olsen DA,Brandslund I,Lillevang ST,Madsen JS,Frederiksen JL,Asgari N

    更新日期:2020-09-01 00:00:00

  • Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

    abstract:BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.001

    authors: Mao Z,Álvarez-González C,Allen-Philbey K,De Trane S,Yildiz O,Campion T,Adams A,Turner BP,Marta M,Gnanapavan S,Espasandin M,Mathews J,Giovannoni G,Baker D,Schmierer K

    更新日期:2019-01-01 00:00:00

  • The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis.

    abstract:INTRODUCTION:Some studies have indicated the importance of considering smoking, vitamin D deficiency and obesity as negative prognostic factors for clinical and MRI outcomes in multiple sclerosis (MS). This study aimed to evaluate the possible effects of these modifiable risk factors on brain MRI lesion burden of patie...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101886

    authors: Lorefice L,Destro F,Fenu G,Mallus M,Gessa I,Sechi V,Barracciu MA,Frau J,Coghe G,Carmagnini D,Marrosu MG,Saba L,Cocco E

    更新日期:2019-12-09 00:00:00

  • Neuromyelitis optica spectrum disorders in Algeria: A preliminary study in the region of Tizi Ouzou.

    abstract:BACKGROUND:Neuromyelitis optica (NMO) is a disabling inflammatory condition that targets astrocytes in the optic nerves and spinal cord. Recent advances led to the individualization of a set of conditions now referred as NMO spectrum disorder (NMOSD). OBJECTIVE:To describe the prevalence and characteristics of NMO SD ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.12.005

    authors: Daoudi S,Bouzar M

    更新日期:2016-03-01 00:00:00

  • COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

    abstract:BACKGROUND:Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102120

    authors: Novi G,Mikulska M,Briano F,Toscanini F,Tazza F,Uccelli A,Inglese M

    更新日期:2020-07-01 00:00:00

  • Neural cell adhesion molecules in brain plasticity and disease.

    abstract::Neural cell adhesion molecule (NCAM) has been studied extensively. But it is only in recent times that interest in this molecule has shifted to conditions such as Alzheimer's disease, Multiple Sclerosis and Schizophrenia, focusing on its role in neurodegeneration and abnormal neurodevelopment. NCAM is important in neu...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2012.08.002

    authors: Gnanapavan S,Giovannoni G

    更新日期:2013-01-01 00:00:00

  • Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.

    abstract:BACKGROUND:Several disease-modifying therapies (DMT) are being used in paediatric patients with multiple sclerosis (MS) despite the limited number of randomised controlled clinical trials leading to approved indication in children. OBJECTIVES:The aim of this study was to describe clinical characteristics of the Danish...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101431

    authors: Erdal JL,Kopp TI,Blinkenberg M,Petersen T,Sørensen PS,Magyari M

    更新日期:2020-01-01 00:00:00

  • Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.

    abstract::Thrombotic microangiopathy (TMA) is a rare but increasingly recognized complication of interferon-beta therapy, which can be associated with serious sequelae. We report on a 53-year-old woman with a longstanding history of relapsing-remitting multiple sclerosis, who developed TMA after 15 years of high-dose treatment ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.09.002

    authors: Gerischer LM,Siebert E,Janke O,Jungehuelsing GJ,Ruprecht K

    更新日期:2016-11-01 00:00:00

  • Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations.

    abstract:OBJECTIVE:To describe 2 atypical cases with Anti-MOG antibody related demyelinating syndrome. METHODOLOGY:Case series. RESULTS:We present two cases. Case 1 is an 18-year-old woman who presented with headache, blurred vision, and papilledema and was initially diagnosed with pseudotumor cerebri syndrome. CSF showed mil...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.10.003

    authors: Narayan RN,Wang C,Sguigna P,Husari K,Greenberg B

    更新日期:2019-01-01 00:00:00

  • Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania.

    abstract:AIM OF THE STUDY:To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS:Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.02.016

    authors: Duchovskiene N,Mickeviciene D,Jurkeviciene G,Dirziuviene B,Balnyte R

    更新日期:2017-04-01 00:00:00

  • Construct validity and test-retest reliability of the Swedish version of the Acceptance of Chronic Health Conditions Scale.

    abstract::The Acceptance of Chronic Health Conditions Scale was developed to measure acceptance in chronic health conditions like multiple sclerosis (MS) and has been translated into Swedish (The Swedish Acceptance of Chronic Health Conditions Scale). The purpose of the present study was to evaluate construct validity and test-...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.07.033

    authors: Wallin A,Forslin M,Johansson S,Kierkegaard M

    更新日期:2019-10-01 00:00:00

  • Myelorradiculitis due to Varicella Zoster (Elsberg syndrome) as the first symptom of HIV in a patient with Crohn's disease in use of Infliximab.

    abstract::Elsberg syndrome (ES) refers to the combination of myelitis and lumbosacral radiculitis associated with infection caused by the virus of the Herpesviridae family. We present a case of a 52-year-old man with a 9 months diagnosis of Crohn's disease, in use of infliximab with good disease control, complaining of 2 months...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102643

    authors: Santos DH,Carneiro de Oliveira RM,Junior WRF,Olivetti BC

    更新日期:2020-11-25 00:00:00

  • Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

    abstract::A 34-year old Caucasian female was initially diagnosed with multiple small-vessel strokes at age 20 years which were etiologically classified as secondary to anti-phospholipid antibody syndrome (APS) although she had no history or laboratory data to suggest APS. Based on her MRI of brain findings, one of her neurologi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.04.004

    authors: Avasarala JR,Jones JR,Rogers CR

    更新日期:2018-05-01 00:00:00

  • Continuous prediction of secondary progression in the individual course of multiple sclerosis.

    abstract:BACKGROUND:Prediction of the course of multiple sclerosis (MS) was traditionally based on features close to onset. OBJECTIVE:To evaluate predictors of the individual risk of secondary progression (SP) identified at any time during relapsing-remitting MS. METHODS:We analysed a database comprising an untreated MS incid...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.04.004

    authors: Skoog B,Tedeholm H,Runmarker B,Odén A,Andersen O

    更新日期:2014-09-01 00:00:00

  • Could Sars-Cov2 affect MS progression?

    abstract::A long-term neurologic sequela arising from COVID-19 infection in multiple sclerosis (MS) patients could be related both to the increase of cytokines and the activation of NLRP3 inflammasome by the Sars-CoV2. These two mechanisms may cause a worsening of MS several months after the resolution of the infection. ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102540

    authors: Di Stadio A,Romani L,Bernitsas E

    更新日期:2020-11-01 00:00:00

  • Pharmacotherapy in multiple sclerosis-induced cognitive impairment: A systematic review and meta-analysis.

    abstract::Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) commonly complicated by cognitive impairment. Unfortunately, no medical therapy has been proved to improve cognitive problems in these patients. This meta-analysis investigated the effectiveness of different categories...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102478

    authors: Motavalli A,Majdi A,Hosseini L,Talebi M,Mahmoudi J,Hosseini SH,Sadigh-Eteghad S

    更新日期:2020-11-01 00:00:00

  • Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015.

    abstract:BACKGROUND:The epidemiology of multiple sclerosis (MS) and neuromyelitis optica (NMO) remains to be clarified or updated in many parts of Asia. This study aims to investigate the epidemiology and comorbidities of MS and NMO during 2001-2015 in Taiwan. METHODS:We conducted a retrospective nationwide population-based st...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102425

    authors: Fang CW,Wang HP,Chen HM,Lin JW,Lin WS

    更新日期:2020-10-01 00:00:00

  • Clinical and radiological profile of neuromyelitis optica spectrum disorders in an Ecuadorian cohort.

    abstract:BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is a complex disease characterized by a severe inflammation of the central nervous system (CNS). This disease typically manifests with recurrent optic neuritis (ON) and acute transverse myelitis (ATM). The clinical and radiological spectrum of NMOSD is little kn...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102208

    authors: Edgar Patricio CD,Eleanor THG,Francisco José CZ,Gabriela ACM,Hyland AO,Fernando GL,María TA,Beatriz N,Marcos SD,Alfredo GPW

    更新日期:2020-09-01 00:00:00

  • Speech discrimination impairments as a marker of disease severity in multiple sclerosis.

    abstract:BACKGROUND:Multiple Sclerosis (MS) pathology is likely to disrupt central auditory pathways, thereby affecting an individual's ability to discriminate speech from noise. Despite the importance of speech discrimination in daily communication, it's characterization in the context of MS remains limited. This cross-section...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102608

    authors: Iva P,Fielding J,Clough M,White O,Noffs G,Godic B,Martin R,van der Walt A,Rajan R

    更新日期:2020-11-01 00:00:00

  • Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States.

    abstract:BACKGROUND:As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2021.102788

    authors: Ehde DM,Roberts MK,Herring TE,Alschuler KN

    更新日期:2021-01-22 00:00:00

  • Access, delivery and perceived efficacy of physiotherapy and use of complementary and alternative therapies by people with progressive multiple sclerosis in the United Kingdom: An online survey.

    abstract:INTRODUCTION:All people with progressive MS in the United Kingdom should have access to physiotherapy through the National Health Service (NHS). However levels of access and delivery are unknown. Furthermore there is no research on perceived efficacy of physiotherapy or the use of complementary and alternative medicine...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.01.002

    authors: Campbell E,Coulter E,Mattison P,McFadyen A,Miller L,Paul L

    更新日期:2017-02-01 00:00:00

  • An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis.

    abstract:BACKGROUND:Notoriously the treatment of multiple sclerosis (MS) is based on the use of several different drugs, characterized by a diverse mechanism of action, efficacy and safety. Recently, progress has been made towards developing new oral immunotherapies, and dimethyl fumarate is the third oral agent approved for th...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.03.009

    authors: Lorefice L,Fenu G,Cabras F,Frau J,Coghe GC,Loi L,Marrosu MG,Cocco E

    更新日期:2016-05-01 00:00:00

  • Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review.

    abstract:BACKGROUND:Research on Virtual Reality (VR) based motor rehabilitation for people with multiple sclerosis (MS) is rapidly growing in popularity, although few studies have focused on the upper limb (UL). The aims of this review were to investigate the effect of VR interventions on UL function in people with MS and deter...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102610

    authors: Webster A,Poyade M,Rooney S,Paul L

    更新日期:2020-10-31 00:00:00

  • Impaired recognition of emotional facial expressions in patients with multiple sclerosis.

    abstract:BACKGROUND:Disturbances that occur in patients with multiple sclerosis (MS) are not restricted to motor, sensory, or urinary functions; they also include cognitive dysfunction, fatigue, and depression. Moreover, people with MS are known to have fewer social activities and a reduced quality of life. One aspect of social...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.02.001

    authors: Berneiser J,Wendt J,Grothe M,Kessler C,Hamm AO,Dressel A

    更新日期:2014-07-01 00:00:00

  • Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study.

    abstract:BACKGROUND:Anti-CD20 monoclonal antibodies such as ocrelizumab, rituximab, and ofatumumab target B-cell lineage. Clinical trials have demonstrated their effect on reducing both magnetic resonance imaging (MRI) active lesion burden as well as clinical activity. Zytux™ (Rituximab, AryoGen Pharmed) used in the present stu...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.101419

    authors: Naser Moghadasi A,Darki A,Masoumi P,Hashemi SN,Ghadiri F

    更新日期:2019-11-01 00:00:00